Erasca ERAS Stock
Erasca Price Chart
Erasca ERAS Financial and Trading Overview
| Erasca stock price | 3.27 USD |
| Previous Close | 1.92 USD |
| Open | 1.93 USD |
| Bid | 1.84 USD x 600 |
| Ask | 1.9 USD x 300 |
| Day's Range | 1.77 - 1.97 USD |
| 52 Week Range | 1.64 - 3.45 USD |
| Volume | 2.21M USD |
| Avg. Volume | 1.46M USD |
| Market Cap | 525.87M USD |
| Beta (5Y Monthly) | 1.161 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.43 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5 USD |
ERAS Valuation Measures
| Enterprise Value | 170.78M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.5135136 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.125908 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.132 |
Trading Information
Erasca Stock Price History
| Beta (5Y Monthly) | 1.161 |
| 52-Week Change | 9.41% |
| S&P500 52-Week Change | 22.67% |
| 52 Week High | 3.45 USD |
| 52 Week Low | 1.64 USD |
| 50-Day Moving Average | 2.71 USD |
| 200-Day Moving Average | 2.57 USD |
ERAS Share Statistics
| Avg. Volume (3 month) | 1.46M USD |
| Avg. Daily Volume (10-Days) | 1.53M USD |
| Shares Outstanding | 282.73M |
| Float | 215.94M |
| Short Ratio | 24.05 |
| % Held by Insiders | 12.38% |
| % Held by Institutions | 87.02% |
| Shares Short | 32.79M |
| Short % of Float | 13.17% |
| Short % of Shares Outstanding | 11.60% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2023 |
| Most Recent Quarter (mrq) | September 30, 2024 |
| Next Fiscal Year End | December 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -150906000 USD |
| Net Income Avi to Common (ttm) | -159119008 USD |
| Diluted EPS (ttm) | -0.79 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 408.41M USD |
| Total Cash Per Share (mrq) | 1.45 USD |
| Total Debt (mrq) | 53.97M USD |
| Total Debt/Equity (mrq) | 11.96 USD |
| Current Ratio (mrq) | N/A |
| Book Value Per Share (mrq) | 1.652 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Erasca
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 3115 Merryfield Row |
| ZIP | 92121 |
| Phone | 858 465 6511 |
| Website | https://www.erasca.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 126 |
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Q&A For Erasca Stock
What is a current ERAS stock price?
Erasca ERAS stock price today per share is 3.27 USD.
How to purchase Erasca stock?
You can buy ERAS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Erasca?
The stock symbol or ticker of Erasca is ERAS.
Which industry does the Erasca company belong to?
The Erasca industry is Biotechnology.
How many shares does Erasca have in circulation?
The max supply of Erasca shares is 283.71M.
What is Erasca Price to Earnings Ratio (PE Ratio)?
Erasca PE Ratio is now.
What was Erasca earnings per share over the trailing 12 months (TTM)?
Erasca EPS is -0.43 USD over the trailing 12 months.
Which sector does the Erasca company belong to?
The Erasca sector is Healthcare.
Erasca ERAS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23578.13 USD — |
+0.31
|
7.36B USD — | 23506 USD — | 23680.03 USD — | — - | 7.36B USD — |
| US Tech Global Select Market Com NQGS | 11556.08 USD — |
+0.33
|
— — | 11519.72 USD — | 11605.16 USD — | — - | — — |
| US Tech Biotechnology NBI | 5738.87 USD — |
-0.45
|
— — | 5719.89 USD — | 5783.12 USD — | — - | — — |
| US Tech Health Care IXHC | 1198.62 USD — |
-0.27
|
— — | 1196.61 USD — | 1205.97 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}